Neoadjuvant Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Cadonilimab for Resectable Hepatocellular Carcinoma: A Single-Arm Phase II Clinical Trial
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Cadonilimab (Primary) ; Camrelizumab (Primary) ; Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TALENP001
- 24 Sep 2024 Status changed from not yet recruiting to recruiting.
- 28 Aug 2024 New trial record